Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 6Terminated 3Active not recruiting 3Unknown 2Not yet recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Burkitt Lymphoma 8Recurrence 3Neoplasm, Residual 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Hodgkin Disease 1Down Syndrome 1Blast Crisis 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4blinatumomab 3Rituximab 3Lenalidomide 2Immunotherapy, Adoptive 2venetoclax 1trastuzumab deruxtecan 1tisagenlecleucel 1pembrolizumab 1obinutuzumab 1niraparib 1nilotinib 1isatuximab 1acalabrutinib 1Zymosan 1Whole-Body Irradiation 1Trastuzumab 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Pentostatin 1NKTR-255 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Immunotherapy 1Imatinib Mesylate 1Histamine Antagonists 1Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × blinatumomab × Clear all
NCT04521231 2026-05-28

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Amgen

Phase 1/2 Active not recruiting
181 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen

Phase 1/2 Active not recruiting
104 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05182385 2025-07-25

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Goethe University

Phase 1/2 Active not recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡